Caputo A, Rossi C, Bozzini R, Betti M, Grossi M P, Barbanti-Brodano G, Balboni P G
Institute of Microbiology, School of Medicine, University of Ferrara, Italy.
Gene Ther. 1997 Apr;4(4):288-95. doi: 10.1038/sj.gt.3300393.
A series of retroviral vectors with potential anti-tat and antirev activity was developed. Vectors containing a tat transdominant negative mutant (tat22/37) and an RRE decoy in different positions, directed by the same promoter or by different promoters, were generated. Retroviral vectors containing tat22/37 and the RevM10 transdominant negative mutant were also constructed. Jurkat cells were transduced with the recombinant retroviruses to produce monoclonal and polyclonal cultures. In these cell lines the recombinant proviruses were correctly integrated and expression of the inserted genes was detected by Northern blot or RT-PCR analysis. However, infection of these cell lines with HIV-1 showed that none of these recombinant constructs inhibited virus replication at a high multiplicity of infection (MOI). At a low MOI, two cell clones containing tat22/37 and the RRE decoy in 3' position showed a long lasting protection against virus replication, in comparison to control cultures expressing tat22/37 or RRE alone. Combination of tat and rev mutants was ineffective in inhibiting HIV-1 replication at both low and high MOIs. At a low MOI, HIV-1 replication was efficiently blocked in two cell clones expressing the RevM10 mutant alone. These results show a synergic effect of anti-tat and anti-rev molecules when the RRE sequence is cloned 3' to tat22/37, suggesting the possibility of using this vector design to control HIV-1 replication.
开发了一系列具有潜在抗tat和抗rev活性的逆转录病毒载体。构建了在不同位置含有tat反式显性负突变体(tat22/37)和RRE诱饵序列的载体,这些载体由相同启动子或不同启动子驱动。还构建了含有tat22/37和RevM10反式显性负突变体的逆转录病毒载体。用重组逆转录病毒转导Jurkat细胞以产生单克隆和多克隆培养物。在这些细胞系中,重组前病毒正确整合,通过Northern印迹或RT-PCR分析检测到插入基因的表达。然而,用HIV-1感染这些细胞系表明,在高感染复数(MOI)下,这些重组构建体均未抑制病毒复制。在低MOI下,与单独表达tat22/37或RRE的对照培养物相比,两个在3'位置含有tat22/37和RRE诱饵序列的细胞克隆显示出对病毒复制的持久保护作用。tat和rev突变体的组合在低MOI和高MOI下均无法有效抑制HIV-1复制。在低MOI下,单独表达RevM10突变体的两个细胞克隆中HIV-1复制被有效阻断。这些结果表明,当RRE序列克隆在tat22/37的3'端时,抗tat和抗rev分子具有协同作用,并提示了使用这种载体设计来控制HIV-1复制的可能性。